Dexus Industria Reit.

DXI

Dexus Industria REIT s an Australian real estate investment trust, which owns interests in a workspace focused portfolio of a number of established, industrial, technology park and business park assets located across Sydney, Melbourne, Brisbane and Adelaide. The company is headquartered in Melbourne, Victoria and currently employs 0 full-time employees. The company went IPO on 2013-12-03. DXI owns, manages and develops industrial warehouses and business parks, and has invested in the operations of the Jandakot Airport industrial precinct. DXI has capabilities in property investment, funds management, and asset management and development. The Company’s property portfolio comprises interests in approximately 93 properties located across Sydney, Melbourne, Brisbane, Perth, and Adelaide. Its properties include 56 Berry Street, North Sydney; 100 Mount Street, North Sydney; 101 George Street, Parramatta; 130 George Street, Parramatta; 100-130 Harris Street, Pyrmont; One Margaret Street, Sydney; Pitt Street Precinct, Sydney; 33 Alfred Street, Sydney; 1 Bligh Street, Sydney; 60 Castlereagh Street, Sydney; 309-321 Kent Street, Sydney; 14-18 Lee Street, Sydney; 44 Market Street, Sydney; 5 Martin Place, Sydney; 25 Martin Place, Sydney, and 175 Pitt Street, Sydney.

DXN Limited

DXN

DXN Ltd. engages in the construction of data center modules and sale to third-party data center owners. The Company’s core business is designing, engineering, manufacturing, maintaining and operating data centers. The Company’s divisions include Modular Division and Data Centre Operations. The Modular Division designs, engineers, manufactures, and deploys EDGE facilities and critical DC infrastructure. The Data Centre Operations division operates, maintains and markets data centers and critical infrastructure for its own DXN data centers, as well as its modular customers. Its solutions include DXN Modules/ Built to order, Edge Data Centers, Micro Edge, DXN-SYDO1 and others. Its Edge Data Centre solutions are designed and deployed to meet its customers individual needs at the Edge. Its DXN-SYD01 has been built to offer a complete and comprehensive colocation solution. Its range of services include engineering, project management, data center management and maintenance and support.

Dimerix Limited

DXB

Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is focused on developing new therapies in areas with unmet medical needs for global markets. The company is focused on developing its products, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its DMX-200 and DMX-700 are identified using its assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. The company has completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease. Receptor-HIT is licensed to Excellerate Bioscience.